Clinical trial
Topotecan in Treating Patients With Recurrent Brain Tumors
NCT00003372 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00003372 |
|---|---|
| Title | Topotecan in Treating Patients With Recurrent Brain Tumors |
| Official title | A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | topotecan hydrochloride |
| Enrollment | 17 |
| Start date | Dec 8, 1997 |
| Primary completion | Oct 5, 2000 |
| Completion | Dec 21, 2009 |
| First posted | Jun 9, 2004 |
| Last update posted | Apr 8, 2020 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: